Nafamostat–Interferon-α Combination Suppresses SARS-CoV-2 Infection In Vitro and In Vivo by Cooperatively Targeting Host TMPRSS2

Nafamostat–Interferon-α Combination Suppresses SARS-CoV-2 Infection In Vitro and In Vivo by Cooperatively Targeting Host TMPRSS2

SARS-CoV-2 and its vaccine/immune-escaping variants continue to pose a serious threat to public health due to a paucity of effective, rapidly deployable, and widely available treatments. Here, we address these challenges by combining Pegasys (IFNα) and nafamostat to effectively suppress SARS-CoV-2 i...

Full description

Bibliographic Details
Main Authors: Aleksandr Ianevski, Rouan Yao, Hilde Lysvand, Gunnveig Grødeland, Nicolas Legrand, Valentyn Oksenych, Eva Zusinaite, Tanel Tenson, Magnar Bjørås, Denis E. Kainov
Format: Article
Language:English
Published: MDPI AG 2021-09-01
Series:Viruses
Subjects:
SARS-CoV-2
interferon-alpha
nafamostat
antiviral drug combination
broad-spectrum antivirals
Online Access:https://www.mdpi.com/1999-4915/13/9/1768

Internet

https://www.mdpi.com/1999-4915/13/9/1768

Similar Items